LGVN
Longeveron LLCNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$33.97M
P/E Ratio
—
EPS
$-1.38
Beta
-0.19
52W High
$1.83
52W Low
$0.47
50-Day MA
$0.71
200-Day MA
$0.84
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Longeveron LLC
Longeveron Inc., a clinical-stage biotechnology company, is dedicated to developing cell therapies for life-threatening and aging-related conditions. The company is headquartered in Miami, Florida.
Fundamentals
| Revenue (TTM) | $1.20M |
| Gross Profit (TTM) | 803,000 |
| EBITDA | $-22.06M |
| Operating Margin | -1479.00% |
| Return on Equity | -164.70% |
| Return on Assets | -81.30% |
| Revenue/Share (TTM) | $0.07 |
| Book Value | $0.25 |
| Price-to-Book | 5.52 |
| Price-to-Sales (TTM) | 28.33 |
| EV/Revenue | 22.93 |
| EV/EBITDA | -49.61 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -39.50% |
| Shares Outstanding | $27.80M |
| Float | $19.82M |
| % Insiders | 7.27% |
| % Institutions | 6.12% |
Analyst Ratings
Consensus ($5.48 target)
1
Strong Buy1
BuyData last updated: 4/8/2026